Payment & Shipping Terms:
|Product Name:||Dexamethasone Injection||Composition:||Each 1mL Ampule Contains:4MG Dexamethasone|
|Indications:||Coriticosteroids Are Used Where Their Anti-inflammatory And Immunosuppressive Effects Are Desirable||Storage Instructions:||Store In Airtight Containers.Protect From Light|
|Expiration Date:||3 Years|
DEXAMETHASONE INJECTION 4MG/1ML
Each 1mL contains 4.0 mg dexamethasone phosphate as the disodium salt.
Dexamethasone phosphate is a glucocorticoid and acts by controlling the rate of protein synthesis. It forms a steroid- receptor complex with receptor proteins, moves into the nucleus where it binds the chromatin and thus directs the genetic apparatus to transcribe RNA. It has a biological half -life in plasma of about 190 minutes. It has little or no effect on sodium and water retention.
Coriticosteroids are used where their anti- inflammatory and immunosuppressive effects are desirable, including intensive treatment during shorter periods.
Dexamethasone phosphate is contra- indicated in a patient that has hypersensitivity to corticosteroids, tuberculosis, psychoses, severe psychoneuroses, acute infection, peptic ulcer or osteoporosis.
The safety in pregnancy and lactation has not been established.
MICRO DEXAMETHASONE PHOSPHATE INJECTION should not be administered intrathecally or subconjuctivally.
Toxic effects may result from withdrawal or from continued use or large doses. Dexamethasone phosphate should be used with extreme caution in the presence of congestive heart failure, hypertension, in patients with diabetes mellitus, epilepsy, glaucoma, ocular herpes simplex, infectious diseases, chronic renal failure, uraemia and in elderly patients.
DOSAGE AND DIRECTIONS FOR USE:
Usual adult dosage ranges from 0,5 to 20 mg daily depending on the severity of the disorder.
Dexamethasone phosphate may be administered by slow intravenous injection or intramuscularly. In the treatment of cerebral oedema caused by malignancy, an initial intravenous dose of 10 mg is usually given, followed by 4 mg intramuscularly, every 6 hours. A response is usually obtained after 12 to 24 hours and dosage may be reduced after 2 to 4 days.
The injection may also be given by intra- articular, intralesional, intramuscular or soft tissue injection. For intra-articular injection, dose equivalent to 0,8 to 4 mg (depending on the size of the joint), are given.
SIDE EFFECTS AND SPECIAL PRECAUTIONS:
Dexamethasone phosphate has little or no effect on sodium and water retention. Oedema, hypertension and an increased excretion of potassium with the possibility of hypokalaemic alkalosis may occur. In extreme cases, cardiac failure may be induced.
Excessive metabolic effects may lead to mobilisation of calcium and phosphorous, with osteoporosis and spontaneous fractures, nitrogen depletion and hyperglycaemia with accentuation or precipitation of the diabetic state. The insulin requirements of diabetic patients are increased. Increased appetite is reported.
The effect on tissue repair is manifest in delayed wound healing and increased susceptibility to all kinds of infection: including sepsis, fungal and viral infections have been reported.
Acute adrenal insufficiency may occur during prolonged treatment or on cessation of treatment and may be precipitated by an infection or trauma. Growth retardation in children has been reported.
Patients with active or doubtfully quiescent tuberculosis should not be given corticosteroids. Similarly, patients already receiving corticosteroid therapy are more susceptible to infection, the symptoms of which, moreover, may be masked until an advanced stage has been reached. Warnings have recently been issued about the risks of chickenpox and severe herpes zoster being increased in patients receiving systematic corticosteroids, and patients should avoid close personal contact with either infection.
Store below 25°C. Protect from light. Keep out of reach of children.